NERV: Minerva Neurosciences, Inc. Stock

by  •  • Comments Off on NERV: Minerva Neurosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 11.68
Enterprise Value ($M) 50.32
Book Value ($M) -25.69
Book Value / Share -3.67
Price / Book -0.45
NCAV ($M) -40.57
NCAV / Share -5.80
Price / NCAV -0.29

Profitability (mra)
Return on Invested Capital (ROIC) 0.04
Return on Assets (ROA) 0.03
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 7.85
Current Ratio 7.85

Balance Sheet (mrq) ($M)
Current Assets 22.27
Assets 37.14
Liabilities 62.84
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -21.85
Net Income 1.44
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -19.55
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Fmr Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-10 5,989 33,089 18.10
2025-03-07 2,981 20,372 14.63
2025-03-06 621 7,599 8.17
2025-03-05 2,761 17,769 15.54

(click for more detail)

Similar Companies
MTVA – MetaVia Inc. MYNZ – Mainz Biomed N.V.
NATR – Nature's Sunshine Products, Inc. NKTR – Nektar Therapeutics
NLSP – NLS Pharmaceutics AG


Financial data and stock pages provided by
Fintel.io